Oryzon Genomics (Spain) Analysis
| ORY Stock | EUR 1.58 0.04 2.60% |
Oryzon Genomics SA is overvalued with Real Value of 1.38 and Hype Value of 1.58. The main objective of Oryzon Genomics stock analysis is to determine its intrinsic value, which is an estimate of what Oryzon Genomics SA is worth, separate from its market price. There are two main types of Oryzon Genomics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Oryzon Genomics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Oryzon Genomics' stock to identify patterns and trends that may indicate its future price movements.
The Oryzon Genomics stock is traded in Spain on Madrid Exchange, with the market opening at 09:00:00 and closing at 17:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Spain. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Oryzon Genomics' ongoing operational relationships across important fundamental and technical indicators.
Oryzon |
Oryzon Stock Analysis Notes
About 18.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.65. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oryzon Genomics SA recorded a loss per share of 0.09. The entity had not issued any dividends in recent years. Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain. ORYZON GENOMICS operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 40 people. To find out more about Oryzon Genomics SA contact the company at 34 93 515 13 13 or learn more at https://www.oryzon.com.Oryzon Genomics SA Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Oryzon Genomics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Oryzon Genomics SA or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Oryzon Genomics SA generated a negative expected return over the last 90 days | |
| Oryzon Genomics SA may become a speculative penny stock | |
| Net Loss for the year was (4.69 M) with profit before overhead, payroll, taxes, and interest of 9.87 M. | |
| Oryzon Genomics SA has accumulated about 29.11 M in cash with (3.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 18.0% of the company outstanding shares are owned by corporate insiders |
Oryzon Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 140.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oryzon Genomics's market, we take the total number of its shares issued and multiply it by Oryzon Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Oryzon Profitablity
Oryzon Genomics' profitability indicators refer to fundamental financial ratios that showcase Oryzon Genomics' ability to generate income relative to its revenue or operating costs. If, let's say, Oryzon Genomics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Oryzon Genomics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Oryzon Genomics' profitability requires more research than a typical breakdown of Oryzon Genomics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.33) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.72) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.72. Technical Drivers
As of the 11th of December 2024, Oryzon Genomics holds the Coefficient Of Variation of (508.41), variance of 1.99, and Risk Adjusted Performance of (0.14). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oryzon Genomics, as well as the relationship between them.Oryzon Genomics SA Price Movement Analysis
The output start index for this execution was fifty-nine with a total number of output elements of two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Oryzon Genomics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Oryzon Genomics SA. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Oryzon Genomics Outstanding Bonds
Oryzon Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oryzon Genomics SA uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oryzon bonds can be classified according to their maturity, which is the date when Oryzon Genomics SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Oryzon Genomics Predictive Daily Indicators
Oryzon Genomics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Oryzon Genomics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 1868.33 | |||
| Daily Balance Of Power | 1.0 | |||
| Rate Of Daily Change | 1.03 | |||
| Day Median Price | 1.56 | |||
| Day Typical Price | 1.57 | |||
| Price Action Indicator | 0.04 | |||
| Period Momentum Indicator | 0.04 |
Oryzon Genomics Forecast Models
Oryzon Genomics' time-series forecasting models are one of many Oryzon Genomics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oryzon Genomics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Oryzon Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Oryzon Genomics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Oryzon shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Oryzon Genomics. By using and applying Oryzon Stock analysis, traders can create a robust methodology for identifying Oryzon entry and exit points for their positions.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain. ORYZON GENOMICS operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 40 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Oryzon Genomics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Complementary Tools for Oryzon Stock analysis
When running Oryzon Genomics' price analysis, check to measure Oryzon Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oryzon Genomics is operating at the current time. Most of Oryzon Genomics' value examination focuses on studying past and present price action to predict the probability of Oryzon Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oryzon Genomics' price. Additionally, you may evaluate how the addition of Oryzon Genomics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |